COLLABORATE El Meu Clínic .This link opens in a new tab.
COLLABORATE El Meu Clínic .This link opens in a new tab.
Make a donation
Navigation thread
Navigation thread
Viral, genetic and immune-mediated liver diseases
Make a donation

Research lines

  • Elimination and biomarkers in viral hepatitis

    Directed by Sabela Lens

    We develop integrated micro-elimination strategies for viral hepatitis (HBV/HDV/HCV) within the Hospital Clínic area and the C17 network, focusing on vulnerable populations. We combine screening, on-site diagnosis and treatment with the identification of virological biomarkers in blood and liver to improve diagnosis, clinical monitoring, and therapeutic management, contributing to the WHO 2030 elimination goals.

  • Immune response in hepatitis B and D

    Directed by Sabela Lens

    We investigate the mechanisms of the immune response in chronic HBV and HDV infection to identify determinants of viral control, disease progression, and treatment response. We use innovative technologies (omics, single-cell and spatial analysis) to characterize virus–host interactions in the liver and blood, with the aim of developing new immunotherapeutic strategies and predictive biomarkers of response.

  • Autoimmune and cholestatic liver diseases

    Directed by Maria Carlota Londoño

    Research focuses on autoimmune and cholestatic liver diseases, including autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, and genetic cholestatic disorders. The group studies disease pathogenesis, prognostic and treatment-response biomarkers, and the natural history of these conditions. Current projects include risk stratification tools, validation of therapeutic response criteria, evaluation of new therapies, and studies on symptoms such as fatigue and pruritus to improve outcomes and patients’ quality of life.

  • Epidemiology of drug-induced liver injury and Wilson’s disease

    Directed by Xavier Forns

    We analyze the epidemiology and clinical impact of drug-induced liver injury (DILI), including medications, herbals, and supplements, in both hospital and community settings. In parallel, we develop and validate biomarkers in Wilson’s disease to optimize diagnosis and monitoring. The aim is to improve early detection and personalize the management of these liver diseases.